EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Total Inventories : $0.00 Mil (As of Jun. 2018)

View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings Total Inventories?

EOM Pharmaceutical Holdings's total inventories for the quarter that ended in Jun. 2018 was $0.00 Mil. EOM Pharmaceutical Holdings's average total inventories from the quarter that ended in Mar. 2018 to the quarter that ended in Jun. 2018 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. EOM Pharmaceutical Holdings's Net-Net Working Capital per share for the quarter that ended in Jun. 2018 was $0.58.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

EOM Pharmaceutical Holdings Total Inventories Historical Data

The historical data trend for EOM Pharmaceutical Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Total Inventories Chart

EOM Pharmaceutical Holdings Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Inventories

Get a 7-Day Free Trial

1.16

1.19

EOM Pharmaceutical Holdings Quarterly Data
	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

EOM Pharmaceutical Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

EOM Pharmaceutical Holdings (OTCPK:IMUC) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

EOM Pharmaceutical Holdings's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2018 is

	Net-Net Working Capital Per Share (Q: Jun. 2018 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.853	+	0.75 * 0	+	0.5 * 0	-	0.402
-	0	-	0)	/	4.19132
=	0.58

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

EOM Pharmaceutical Holdings's Days Inventory for the three months ended in Jun. 2018 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2018 )	/	Cost of Goods Sold (Q: Jun. 2018 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

EOM Pharmaceutical Holdings's Inventory Turnover for the quarter that ended in Jun. 2018 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2018 )	/	Average Total Inventories (Q: Jun. 2018 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

EOM Pharmaceutical Holdings's Inventory to Revenue for the quarter that ended in Jun. 2018 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2018 )	/	Revenue (Q: Jun. 2018 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

EOM Pharmaceutical Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645

Website

https://www.eompharma.com

EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.

Executives

Andrew Gengos	director	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus	director, officer: Chairman and Secretary	SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg	director	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi	director	246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin	director	C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell	director	7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender	officer: VP, Product Development & Mfg.	112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh	director, officer: President & CEO	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne	director	649 STONE CANYON ROAD, LOS ANGELES CA 90077